2026-04-05T12:42:32Zhttps://recercat.cat/oai/request
oai:recercat.cat:11351/100872025-10-24T08:28:06Zcom_2072_451660com_2072_378040col_2072_451662
RECERCAT author Guerra, Ivan author Mañosa Ciria, Míriam author Casanova, María José author de la Peña Negro, Luisa Carmen author Bujanda, Luis author Piqueras, Marta author Pérez-Martínez, Isabel 2025-10-24T08:28:06Z 2025-10-24T08:28:06Z 2023-08-14T11:44:49Z2023-08-14T11:44:49Z2023-01-25 http://hdl.handle.net/11351/10087 Inflammatory bowel disease; Lymphoma; ThiopurinesEnfermedad inflamatoria intestinal; Linfoma; TiopurinasMalaltia inflamatòria de l'intestí; Limfoma; TiopurinesAn increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies. Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Intestins - Inflamació Limfomes Factor de necrosi tumoral DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Monokines::Tumor Necrosis Factor-alpha ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::monocinas::factor de necrosis tumoral alfa Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion